

The invention relates to a novel, orally administered form of presentation for the agent 3-[(2-([4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl)-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] propionic acid ethyl ester and the pharmaceutically compatible salts thereof.